MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 28, 2008; DOI: 10.1124/mol.107.042838


0026-895X/08/7401-109-121$20.00
Mol Pharmacol 74:109-121, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.107.042838v1
74/1/109    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Lindström, T. M.
Right arrow Articles by Bennett, P. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lindström, T. M.
Right arrow Articles by Bennett, P. R.

Histone Deacetylase Inhibitors Exert Time-Dependent Effects on Nuclear Factor-{kappa}B but Consistently Suppress the Expression of Proinflammatory Genes in Human Myometrial Cells

Tamsin M. Lindström, Aarthi R. Mohan, Mark R. Johnson, and Phillip R. Bennett

Department of Reproductive Biology, Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, London, United Kingdom (T.M.L., A.R.M., P.R.B.); and Department of Maternal and Fetal Medicine, Chelsea and Westminster Hospital, Imperial College London, London, United Kingdom (M.R.J.)

Premature activation of the inflammatory processes that mediate human parturition leads to preterm birth, a major clinical problem associated with neonatal morbidity and mortality. Histone deacetylase inhibitors (HDACi) are currently in clinical trials for the treatment of inflammatory disorders. Recent evidence suggests that there may be a therapeutic use for HDACi in the management of preterm birth, with administration of HDACi to pregnant mice shown to delay delivery. Because NF-{kappa}B is a key orchestrator of the inflammatory response and plays a pivotal role in parturition, it is important to understand how administration of HDACi might affect NF-{kappa}B activity in human uterine tissues. We show here that the effects of HDACi on nuclear factor-{kappa}B (NF-{kappa}B) in human myometrial cells are time-dependent. Short-term exposure to HDACi enhanced interleukin (IL)-1β-induced NF-{kappa}B activity as a result of potentiating I{kappa}B kinase (IKK)β activity, thereby leading to persistent turnover of I{kappa}B{alpha}/{epsilon} proteins and prolonging NF-{kappa}B phosphorylation, nuclear localization, and DNA binding. Conversely, long-term HDACi treatments resulted in repression of NF-{kappa}B DNA binding. Nevertheless, both short- and long-term HDACi treatments inhibited the expression of four labor-associated proinflammatory genes (COX-2, IL-8, IL-6, and RANTES), and this was associated with repression of the proinflammatory transcription factor c-Jun. Together, our data indicate that HDACi exert anti-inflammatory effects in human myometrium and may thus be useful in achieving a myometrial gene expression profile that favors uterine quiescence. However, coadministration of an IKKβ inhibitor may be both necessary and sufficient to circumvent potential induction of labor-associated pathways that could result from HDACi-induced augmentation of NF-{kappa}B activity.


Received November 9, 2007; accepted March 28, 2008

Address correspondence to: Dr. Tamsin M Lindström, 3rd Floor IRDB, Imperial College London, Hammersmith Campus, Du Cane Rd., London W12 0NN, UK. E-mail: tamsinlindstrom{at}gmail.com







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics